Since the beginning of the pandemic, more than one million people hospitalised with COVID-19 have been treated with Actemra worldwide Basel, 21 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today ...
When Sanofi and Regeneron’s Kevzara and Roche’s Actemra both flopped in trials in COVID-19 patients, it looked like the end of road for targeting IL-6 to control coronavirus-related pneumonia. But now ...
– EMPACTA is the first global Phase III trial to show efficacy with Actemra in COVID-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patients – “The ...
ZURICH (Reuters) - Roche's <ROG.S> Actemra helped the sickest COVID-19 patients in a 303-patient study, the trial's lead investigator said on Thursday, bolstering what has been mixed evidence that the ...
Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...
– Medicine offers a new option for children living with a rare and severe form of arthritis – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX ...
Swiss drug maker Roche will mix Remdesivir with Actemra to see the efficacy in treating Covid-19 Roche is hoping that by combining the two in a global study of 450 hospitalised patients worldwide, it ...
Roche Holding AG RHHBY announced that the FDA has accepted the company’s Supplemental Biologics License Application (sBLA) for arthritis drug Actemra for the treatment of giant cell arteritis (GCA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results